1-hydrocarbylamino-3-(ortho-furylmethyloxyphenoxy or tetrahydrofurylmethyloxy-phenoxy)-2-propanol compounds

ABSTRACT

Phenoxy-aminopropanol derivatives of the formula   WHEREIN R1 is furylmethyl, thienylmethyl, tetrahydrofurylmethyl, pyridylmethyl, or a group of the formula R-X-A-, wherein R is C1 4 alkyl, C1 4 alkenyl, phenyl or benzyl, X is -O- or -S-, and A is C1 4 alkylene or -CH2C*CCH2-; -N(R2)(R3) is C1 4 alkylamino, dialkylamino (each alkyl being at most four carbon atoms), cyclohexylamino, piperidino, morpholino or 4-methyl-1piperazinyl; and R4 is H, CH3 or Cl, and pharmaceutically acceptable acid addition salts thereof, are useful as Beta adrenergic blocking agents.

Waited States Patent 1 I Nalmnisiii et ad.

[451 Mar. 27, was

i-HYDROCARBYLAMINO-B-(ORTHO- FURYLMETHYLOXYPHENOXY OR TETRAHYDROFURYLMETHYLOXY- PHENOXY)-2-PROPANOL COMPOUNDS Inventors: Michio Nakanishi; Tomio Muro, both of Oita; Hiroshi lmamura,

Chiba; Nobuharu Yamaguchi, Kanagawa, all of Japan Assignee: Yoshitomi Pharmaceutical industries, Ltd., Osaka, Japan Filed: May 15, 1970 Appl. No.: 37,895

Foreign Application Priority Data May 16, 1969 Japan ..44/38l37 Apr. 3, 1970 Japan ..45/28945 Apr. 3, 1970 7 Japan .....45/28946 Oct. 2, 1969 Japan ..44/79477 U-S. Cl. ..260/347.7, 260/247.l, 260/247,

260/268 FT, 260/268 R, 260/293.68, 260/293.73, 260/293.83, 260/296, 260/332.3, 260/570, 424/251, 424/248, 424/263, 424/267, 424/275, 424/285,

424/325 llnt. Cl. ..C07d 5/16, C07d 5/20 Field of Search; ..260/347.7

[56] References Cited UNITED STATES PATENTS 3,203,992 8/1965 Kunz et al ..260/287 X Primary Examiner-Alex Maze! Assistant Examiner-Bernard Dentz Att0rney-Sughrue, Rothwell, Mion, Zinn and Macpeak [57] ABSTRACT Phenoxy-aminopropanol derivatives of the formula 10 Claims, No Drawings IJHVDIRQCARBYLAMINO-Il{ORTHO- FURYLMETHYLOXYPIIENOXY OK i TE'IRAHYDRUIFURYLMETIIYLOXY-PHENOXY)- 2-PROIANOL COMPOUNDS FIELD OF THE INVENTION This invention relates to novel and therapeutically valuable phenoxy-aminopropanol derivatives.

SUMMARY OF THE INVENTION The novel phenoxy-aminopropanol derivatives of this invention are compounds in accordance with the formula wherein R R R and R have the same meaning as above, and Y is a group of the formula or -CH(OH)-CI-I (halogen).

The reaction is usually carried out in an inert solvent such as methanol, ethanol, propanol, isopropanol,

3 V In and pharmaceutically acceptable acid addition salts 2 thereof, where R, is furylmethyl, thienylmethyl, tetrahydrofurylmethyl, pyridylmethy or a group of the formula R-X-A, wherein R is alkyl, alkenyl, phenyl or benzyl (the alkyl or alkenyl group having, at most,

four carbon atoms and including such groups as methyl, ethyl, propyl, isopropyl, butyl or allyl), X is 0- or -S, and A is alkylene (the alkylene group having, at most, four carbon atoms and including such groups as methylene, ethylene, propylene, trimethylene or tetramethylene) or CH CE N(R )(R is alkylor dialkylamino (the alkyl group having, at most, four carbon atoms and including such groups as methyl, ethyl, propyl, isopropyl, butyl, secbutyl or tert-butyl), cyclohexylamino, piperidino,

morpholino or 4-methyl-l-piperazinyl; and R is H,

CH or CI. The compounds of this invention are useful as B-adrenergic blocking agents.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The compounds of formula [I] may be produced by reacting a compound of the formula with a compound of the formula ether, dioxane, tetrahydrofuran, benzene, toluene, xylene, water, dimethylformamide, dimethylsulfoxide or the like (preferably methanol or ethanol), at from room temperature (2030C) to the boiling point of 20 the solvent employed for from several hours to several days.

When a compound of formula II, wherein Y is CI-I(OH)-CI-I (halogen), is used as a starting material, the reaction may be carried out in the presence of an acid acceptor such as potassium carbonate, sodium carbonate, sodium hydroxide, triethylamine or pyridine.

Starting compounds II wherein Y is epoxyethyl may be produced, for example, by reacting a compound of the formula with epichlorhydrin in water in the presence of sodium hydroxide or potassium hydroxide.

A specific example of the preparation of the starting compound II is as follows:

Nine grams of o-(2-methoxyethoxy)phenol is suspended in 50 milliliters of water containing 3.7 grams of potassium hydroxide, and 5.5 grams of epichlorhydrin is added thereto with stirring. The mix- 0 ture is stirred at room temperature for 7 hours, and

It; H l

then extracted with two 50 milliliter portions of benzene. The extract is washed with water, dried over anhydrous magnesium sulfate and the benzene is distilled off to give 8.5 grams of oily l-(2,3-cpoxypropoxy)-2-(IZ-methoxyethoxy)benzene showing m, =l.5257.

A starting compound of formula II, wherein R is agairgtilwpmierenol CH or Cl, may be prepared, for example, from a subea Aur'cuar prepamlon stituted catechol of the formula: preparation Test Contraction force Heart beat number 5 Compound (CH5 or c1)-/ oH P 50 s/ 5 us l A 8.2 0.1 0.1 i OH B 8.3 0.03 0.03 [V] C 8.8 0.03 0.03 D 7.3 0.5 0.5 E 6.4 0.5-1.0 0.1-1.0 Therefore, the compound IV is usually obtained in 10 g 8'2 the form of a mixture consisting of the following H isomers: J 7.9 0.2 0.3 K 8.4 0.l 0.l N 8.3 0.01-0.03 0.01-0.03

(on; or on- OH (CH; or c1 -OR1 In the above table, the compounds designated by letters are as follows: (other exemplary compounds are 0411 given [VI] [VII] A: l-isopropylamino-3-[o-(Z-methoxyethox- 2O y)phenoxy]-2-propanol maleate B: l-isopropylamino-3-(o-methoxymethoxyphenoxy)-2-propanol fumarate In this case, the compound I is obtained in the form of a mixture of the corresponding isomers VI and VII.

The compounds of formula I and their pharmaceuti- D: Y P cally acceptable acid addition salts have strong B-adre- P fumarate V2 hydrate nergic blocking activity as shown, for example, by the E1 P P) p' yp following tests. Y)' 'P 'P fumarate y)-2-propanol w fumarate C: l-tert-butylamino3-(o-methoxymethoxyphenox- The test for B-adrenergic activity which is judged F1 y 'i 4 y from the antagonistic activity of the test compound y)P Y]' "P P Vzfumarate 'khydrate against isoproterenol is carried out by the following G1 y y p p y procedures: yphenoxy)-2-propanol k fumarate l. A tracheal chain preparation, which is prepared l-is0propylamino-3-[o-(2-methoxy-1- from the tracheal muscle of a guinea pig according to methylcthyl)phenoxy]-2-propanol fumarate the method described by K. Takagi et a] in Chemical J: l-sec-butylamino-3-[o-(2-methoxyethoxand Pharmaceutical Bulletin", Vol. 6, 716-720 (1958), y)phenoxy]-2-propanol fumarate 7 is suspended in a 20 ml organ bath containing Tyrode K; 1-sec-butylamino-3-(o-methoxymethoxyphenoxsolution, said bath being maintained at 37C. After y).2 anol%fum r t contraction iS obtained Of acetylcholine L; 1 tert.butylamino-3 .e[hoxymethoxyphenoxy). chloride, isoproterenol is added cumulatively. An- 40 2 pmpano| 1,1 f t tagonistic intensity of the test compound against the ex- 1,tert butylamino..3 (mallyloxymethoxyphenok pansion of the tissue induced with the addition of y) 2 p p l%f t isoproterenol is measured according to the method 1 isopropylamino 3 [o-(Lthiewlmethoxdescribed by J.M. van Rossum et al in Archives Intery)phenoxyl 2 propanol 1/2 fumarate nationales de Pharmacodynamie et de Therapie", Vol. 143 2993300963) 0. l tert butylamino 3 [o (2 thienylmethox y)phenoxy]-2-propanol a fumarate monohydrate I-isopropylamino-3-(o-tetrahydrofurfuryloxyphenoxy)-2-propanol a fumarate A hydrate Q: l-(4-methyl-l-piperazinyl)-3-[o-(2-thienylmethoxy)phenoxy]-2-propanol fumarate Va hydrate R: l-piperidino3-[o-(2-thienylmethoxy)phenoxy]- 2-propanol fumarate S: l-isopropylamino-3-(o-furfuryloxyphenoxy)-2- propanol fumarate 2. An auricular preparation of guinea pig, obtained by a conventional manner, is suspended in a 20 ml organ bath containing Tyrode solution oxygenated with 95% O and 5% CO said bath being maintained at 32C. Antagonistic activity of the test compound against the increase of contraction force and heartbeat number induced with the addition of 10- g/ml of isoproterenol is measured. This test is performed essentially in accordance with the method described by P.M. Lish et al in Journal of Pharmacology and Experimenta] Therapeutics", VOL 149 161473 (1965) T: l-tert-butylamino-3-(o-furfuryloxyphenoxy)-2- The results ofthese tests are set forth in the following Propanol fumarat? hydrate table, wherein pA is the negative of the logarithm to U1 y y Y the base 10, of the molar concentration of the test comyp w- -p p' V2 fumarllle pound which reduces the effect of twice the dose of V1 y -I y hoxisoproterenol on the contracting action of the guinea y)p yl- -pr0p n l 'fumaratc pig tracheal muscle to that of a single dose; IC is the W! y -py y h xconcentration of the test compound which inhibits 50 y)phenoxy]-2-propanol fumarate a hydrate percent of the effect of isoproterenol. Suitable results may also be obtained with the above compounds not specifically listed in the previous Table Antagonistic activity (i.6., L, M and O-W Acute toxicit-ies ofCompound 1 when administered intraperitoneally and/or intravenously to mice are as follows:

1.1),, mg/kg Compound lntraperitoneally intravenously 3 7 5 100-1 50 150 In view of various tests including those mentioned above, the compounds of the present invention represented by formula 1 and pharmaceutically acceptable acid addition salts thereof can be administered safely as B-adrenergic blocking agents for the treatment of angina pectoris, various arrhythmias such as cardiac, continuous, inotropic, juvenile, nodal, perpetual, phasic sinus, respiratory, sinus and vagal arrhythmia, pheochromocytoma and the like, in the form of a pharmaceutical preparation with a suitable and conventional carrier or adjuvant, administrable orally or by way of injection, without harm to the host.

The pharmaceutical preparations may take any conventional form such as tablets, capsules, granules, powders, syrups, injectable solutions, etc.

The following are illustrative examples of formulations to be administered when the compounds of formula I and their acid addition salts are administered for the above pharmaceutical purposes.

a. 10 mg. tablets are prepared from the following composition:

Compound C 12.0 mg.

(equivalent to 10 mg. of the base) lactose 80.0 mg. starch 27.0 mg. magnesium stearate 1.0 mg.

b. 10 mg. capsules are prepared from the following composition:

Compound C 12.0 mg. lactose 70.0 mg. starch 17.0 mg. magnesium stearate 1.0 mg.

0. a 0.1 percent injectable solution is prepared by combining the following:

Compound C 6.0 mg.

sodium chloride 54.0 mg.

water for injection a sufficient quantity to make 5 milliliters The oral daily dose of the compounds of formula 1 or a salt thereof for huma adults usually ranges from about 30 to 60 milligrams.

1n the following illustrative examples of typical and presently preferred embodiments of the invention, g." and ml. represent gram(s)" and milliliter(s), respectively.

EXAMPLE 1 To a solution of 8.0 g. of 1-(2,3-epoxypropoxy)-2-(2- methoxyethoxy)-benzene in 60 ml. of methanol are added 3.5 g. of isopropylamine and 0.7 m1. of water, the mixture is allowed to stand at 2530C for 72 hours, and then the methanol is distilled off. The

residue is dissolved in 5 percent hydrochloric acid and the solution is extracted with two 50 ml. portions of benzene. The aqueous layer is made alkaline with potassium hydroxide and the isolated oil is extracted with benzene. The extract is dried over potassium carbonate and concentrated to give 8.1 g. (80 percent) of 1 -isopropylamino-3-[o-( 2-methoxyethoxy )phenoxy]- 2-propanol melting at 636 5C.

To an ether solution containing 0.28 g. of the product mentioned above is added dropwise a solution of 0.12 g. of maleic acid in 5 ml. of acetone. The precipitated crystals are collected by filtration and recrystallized from a mixture of ethanol and ether to give 0.32 g. of the corresponding acid maleate melting at 5 l-54C.

EXAMPLE 2 To a solution of 5.5 g. of l-bromo-3-(o-methoxymethoxyphenoxy)-2-propanol in 50 ml. of ethanol is added 3.6 g. of piperidine, the mixture is refluxed for 6 hours, and then the ethanol is distilled off. The residue is dissolved in 5 percent oxalic acid and extracted with benzene. The aqueous layer is made alkaline with potassium hydroxide, the isolated oil is extracted with benzene, the benzene layer is dried over potassium carbonate, and then the benzene distilled off to give 4.6 g. of oily l-piperidino-3-(o-methoxymethoxyphenoxy)-2- propanol. Its boiling point is l-l75C/0.1 mml-Ig.

The corresponding acid fumarate recrystallized from a mixture of ethanol and ether melts at l27l28C.

EXAMPLE 3 To a solution of 1.0 g. of l-(2,3-epoxypropoxy)-2-(2- thienylmethoxy)benzene in 15 ml. of methanol are added 1.0 g. of isopropylamine and one drop of water, the mixture is allowed to stand at 25-30C for 72 hours, and then the methanol is distilled off. The residue is dissolved in 50 ml. of benzene and extracted with two 50 ml. portions of 7 percent oxalic aciduThe aqueous layer is made alkaline with potassium hydroxide, and the isolated oil is extracted with benzene. The benzene layer is dried over potassium carbonate and concentrated to give 10 g. of oily l-isopropylamino-Ii- [o-( l-thienylmethoxy)phenoxy]-2-propanol.

The corresponding fumarate recrystallized from a mixture of methanol and ether melts at 179182C.

EXAMPLE 4 To a solution of 3.0 g. of l-chloro-3-[o-(2-thienylmethoxy)phenoxy]-2-propanol in 30 ml. of ethanol is added 1.9 g. of piperidine, the mixture is refluxed for 10 hours, and then the ethanol is distilled off. The residue is dissolved in ether and the insoluble matter is filtered off. The ether solution is extracted with 70 ml. of 7'percent oxalic acid. The aqueous layer is made alkaline with potassium hydroxide and the isolated oil is extracted twice with ether. The ether extract is dried over potassium carbonate and concentrated to give 2.9 g. (83 percent) of oily l-piperidino-3-[o-(2-thienylmethoxy) phenoxy]-2-propanol.

The corresponding acid fumarate recrystallized from a mixture of methanol and ether melts at 148149C.

EXAMPLES To a solution of 2.4 g. of 1-(2,3-epoxypropoxy)-2-(2- methylthioethoxy)benzene in ml. of methanol are added 1.5 g. of tert-butylamine and 0.1 ml. of water, the mixture is allowed to stand at 30C for 72 hours, and then the methanol is distilled off. The residue is dissolved in toluene and the solution is extracted twice with 5 percent oxalic acid. The aqueous extract is made alkaline with potassium hydroxide and the isolated oil is extracted with toluene. The toluene extract is dried over potassium carbonate and concentrated to give 2.5 g. (80percent) of l-tert-butylamino- 3-[o-(2-methylthioethoxy)phenoxy]-2propanol melting at 4546C.

The corresponding fumarate recrystallized from a mixture of ethanol and ether melts at l38140C.

EXAMPLE 6 To a solution of 3.2 g. of l-bromo-3-[o-(2- methylthioethoxy)phenoxy]-2-propanol in ml. of ethanol is added 1.8 g. of piperidine, the mixture is refluxed for 6 hours, and then the ethanol is distilled off. The residue is dissolved in benzene and the solution is extracted twice with 5 percent oxalic acid. The aqueous extract is made alkaline with potassium hydroxide and the isolated oil is extracted with benzene. The benzene extract is dried over potassium carbonate and the benzene is distilled off to give 2.7 g. of oily lpiperidino-3-[o-(2methylthioethoxy)phenoxy]-2- propanol.

The corresponding acid fumarate recrystallized from a mixture of methyl ethyl ketone and ether melts at l03-l06C.

EXAMPLE 7 To a solution of 4.5 g. of an almost equimolar mixture of 1-(2,3-epoxypropoxy)-2-methoxymethoxy-4- methylbenzene and l-(2,3-epoxypropoxy)-2-methoxymethoxy-S-methylbenzene in 45 ml. of methanol are added 1.5 g. of isopropylamine and 0.2 ml. of water, the mixture is allowed to stand at 2530C for 72 hours, and then the methanol is distilled off. The residue is dissolved in benzene and the solution is extracted with two 70 ml. portions of 5 percent oxalic acid. The aqueous extract is made alkaline with potassium hydroxide and the isolated oil is extracted with benzene. The benzene extract is dried over potassium carbonate and concentrated to give 4.5 g. 80 percent) of an oily, almost equimolar mixture of lisopropylamino-3-(2-methoxymethoxy-4- methylphenoxy)-2-propanol and 1-isopropylamino-3- (2-methoxymethoxy-S-methylphenoxy)-2-propanol.

The corresponding fumarate mixture recrystallized from a mixture of ethanol and ether melts at l25-127C.

EXAMPLE 8 To a solution of 3.1 g. of an almost equimolar mixture of 1-bromo-3-(2-methoxymethoxy-4- methylphenoxy)-2-propano1 and 1-bromo-3-(2methoxymethoxy-5-methylphenoxy)-2-propanol in ml. of ethanol is added 2.0 g. of piperidine, the mixture is refluxed for 6 hours, and then the ethanol is distilled off. The residue is dissolved in 70 ml. of 5 percent oxalic acid and the insoluble matter is extracted with benzene. The aqueous layer is made alkaline with potassium hydroxide and the isolated oil is extracted with benzene. The benzene extract is dried over potassium carbonate and the benzene is distilled off to give 2.5 g. of an oily, almost equimolar mixture of 1- piperidino-3-(2-methoxymethoxy-4-methylphenoxy)- 2-propanol and 1-piperidino-3-(2-methoxymethoxy-5- methylphenoxy)-2-propano1 boiling at ll C/0.l mmHg.

Proceeding by the method of the above Examples, but substituting equivalent amounts of appropriate starting materials, the following compounds are also produced:

1. l-(4-methyl-1-piperaziny1)-3-(o-methoxymethoxyphenoxy)-2-propanol dioxalate melting at 187-189C with decomposition;

2. 1-morpholino-3-(o-methoxymethoxyphenoxy)-2- propanol boiling at l55l60C/0.07 mmHg and its fumarate melting at 85-86C;

3. 1-tert-butylamino-3-(o-methoxymethoxyphenoxy)-2-propanol k fumarate melting at 162l63C with decomposition;

l-isopropylamino-3-( p-methoxymethoxyphenoxy)-2-propanol melting at 45-48C and its fumarate melting at 98C;

5. 1-isopropylamino-3-(m-methoxymethoxyphenoxy)-2-propanol boiling at l42C/0.l mmHg and melting at 2530C;

1-piperidino-3-(m-methoxymethoxyphenoxy )-2- propanol boiling at l40-148C/0.05 mmHg;

7. 1-piperidino-3-[o-(2-methoxyethoxy)phenoxy]-2- propanol fumarate melting at 148-151C;

8. 1-morpholino-3-[o-(2methoxyethoxy)phenoxy]- 2-propanol boiling at 142-148C/0.05 mmHg;

9. 1-isopropylamino-3-(o-methoxymethoxyphenoxy)-2-propanol k fumarate melting at 145146C with decomposition;

10. 1-isopropylamino-3-( o-isopropoxymethoxyphenoxy)-2-propano1 boiling at l40-143C/0.08 mmHg;

11. l-isopropylamino-3-[o-(4methoxybutynyloxy)phenoxy]-2-propanol r fumarate h hydrate melting at 89-93C;

12. 1-isopropylamino-3-[o-(2-ethoxyethoxy)phenoxy]-2-propano1 fumarate A hydrate melting at l04l07C;

13. l-isopropylamino-3-[o-(2-methoxy-1- methylethoxy)phenoxy]-2-propanol fumarate melting at l08112C;

14. 1-cyclohexylamino-3-(o-isopropoxymethoxyphenoxy)-2-propanol Va fumarate melting at ll5117C;

15. l-sec-butylamino-3-[o-(2-methoxyethoxy)phenoxy]-2-propano1 k fumarate melting at 85-88C;

l6. 1-sec-butylamino-3-(o-methoxymethoxyphenoxy)-2-propanol k fumarate melting at 125-l27C;

l7. 1tert-butylamino-3-(o-ethoxymethoxyphenoxy)- 2-propanol k fumarate melting at 168l 71C;

18. 1tert-butylamino-3-(o-allyloxymethoxyphenoxy)-2-propanol A fumarate melting at 16l-162C;

19. l-piperidino-3-(o-allyloxymethoxyphenoxy)-2- propanol h fumarate melting at l20-l22C;

20. l-(4-methyl-l-piperazinyl)-3-[o-(2-thienylmethoxy)phenoxy1-2-propanol di)acid fumarate) melting at l58-l 61C;

2 l. l-tert-butylamino-3-[o-(Z-thienylmethoxy)phenoxy]-2-propanol melting at 142-l46C-,

22. l-dimethylamino-3-[o-(Z-thienylmethoxy)phenoxy]-2-propanol oxalate melting at 88-90C;

23. l-isopropylamino-3-(o-furfuryloxyphenoxy)-2- propanol fumarate melting at l64166C;

24. l-tert-butylamino-3-(o-furfuryloxyphenoxy-Z- propanol fumarate h hydrate melting at 142144C;

2S. 1-rnorpholino-3-(o-furfurloxyphenoxy)-2- propanol acid fumarate melting at l38l 42C;

26. l-cyclohexylamino-3-(o-furfuryloxyphenoxy)-2- propanol melting at 1 l9-'I22C;

27. l-isopropylamino-3 -(o-tetrahydrofu rfuryloxyphenoxy)-2 propanol fumarate melting at 135-l 37C;

28. l-tert-butylamino-3 -(o-tetrahydrofurfuryloxyphenoxy)-2-propanol fumarate melting at l28-132C;

29. l-tert-butylamino-3-[o-(3-pyridylmethoxy)phenoxy]-2'-pr0panol fumarate /2 hydrate melting at l42-146C;

30. l-cyclohexylamino-3-[o-( 3-,pyridylmethox- .y)phenoxy]-2-propanol fumarate melting at l38l41C;

31. ltert-butylamino-3-[o-( 2-phenoxyethoxy)phenoxy]-2-propanol fumarate melting at l52l53C',

32. l-tert-butylamino-3-(o-benzyloxymethoxyphenoxy)-2-propanol fumarate melting at l54-156C;

33. 1tert-butylamino-3-(o-methylthiomethoxyphenoxy)-2-propanol fumarate melting at l63165.5;

34. l-(4-methyl-1-piperazinyl)-3-[o-(2- methylthioethoxy)phenoxy1-2-propanol dioxalate melting at 202-203C with decomposition;

3 5. l-morpholino-3-[o-(2-methylthioethoxy)phenoxy]-2-propanol acid fumarate melting at l30133C;

3 6. l-cyclohexylaminc-3-[o-(2-methylthioethoxy)phenoxy]-2'propanol melting at 9093C;

37. Almost equimolar mixture of 1-(4-methyl 1- piperazinyl)-3-(2-methoxymethoxy)-4- methylphenoxy)-2-propanol and l-(4-methyl-lpiperazinyl)-3-(2-methoxymethoxy-5- methylphenoxy)-2-propanol, its dioxalate mixture melting at l87-l 88C;

38. Almost equirnolar mixture of l-tert-butylamino- 3-(2-methoxymethoxy-4-chlorophenoxy)-2- propanol and i-tert-butylamino-3-(2-methoxymethoxy-S-chlorophenoxy)-2-propanol, its fumarate mixture melting at 136-l39C; and

39. Almost equimolar mixture of l-morpholino-3-(2- methoxymethoxyl-methyl-phenaxy)-2-propanol and l-morpholino-3-(2-methoxymethoxy-5- methylphenoxy)-2-propanol boiling at l95C/0.3 mmi-lg.

What is claimed is:

1. A compound selected from the group consisting of phenoxyaminopropanol derivatives of the formula:

wherein R is a member selected from the group consisting of a furylmethyl group and a tetrahydrofuryl' methyl group; N(R )(R is a member selected from the group consisting of an alkylor dialkylamino group, the alkyl group of which has, at most, four carbon atoms, and a cyclohexylamino group; and R is a member selected from the group consisting of a hydrogen atom, a methyl group, and a chlorine atom, as well as the pharmaceutically acceptable acid addition salts thereof.

2. The compound of claim 1:

l-isopropylamino-3-(o-furfuryloxyphenoxy)-2- propanol fumarate.

3. The compound of claim 1:

l-tert-butylamino-3-(o-furfuryloxyphenoxy)-2- propanol fumarate hydrate.

4. The compound of claim ll:

l-cyclohcxylamino-3-(o-furfuryl-oxyphenoxy)-2- propanol.

5. The compound of claim 1:

1-is0propylamino-3-(o-tetrahydrofurfuryloxyphenoxy)-2-propanol fumarate.

6. The compound of claim 1:

l-tert-butylamino-3-( o-tetrahydrofurfuryloxyphenoxy)-2-propanol /2 fumarate.

.7. A compound of claim 1 having the name 1- isopropylamino-3-(o-teti'ahydrofurfuryloxyphenoxy)- Z-propanol.

8. A compound of claim 1 having the name 1- isopropylamino-3-(o-furfuryloxyphenoxy)-2-propanol.

9. A compound of claim 1 having the name l-tert-butylamino-3-(o-furfuryloxyphenoxy)-2-propanol.

10. A compound of claim ll having the name l-tertbutylamino-3-(o-tetrahydrofurfuryloxyphenoxy)-2- propanol.

a t: t: a a: 

2. The compound of claim 1: 1-isopropylamino-3-(o-furfuryloxyphenoxy)-2-propanol fumarate.
 3. The compound of claim 1: 1-tert-butylamino-3-(o-furfuryloxyphenoxy)-2-propanol fumarate 1/2 hydrate.
 4. The compound of claim 1: 1-cyclohexylamino-3-(o-furfuryl-oxyphenoxy)-2-propanol.
 5. The compound of claim 1: 1-isopropylamino-3-(o-tetrahydrofurfuryloxyphenoxy)-2-propanol fumarate.
 6. The compound of claim 1: 1-tert-butylamino-3-(o-tetrahydrofurfuryloxyphenoxy)-2-propanol 1/2 fumarate.
 7. A compound of claim 1 having the name 1-isopropylamino-3-(o-tetrahydrofurfuryloxyphenoxy)-2-propanol.
 8. A compound of claim 1 having the name 1-isopropylamino-3-(o-furfuryloxyphenoxy)-2-propanol.
 9. A compound of claim 1 having the name 1-tert-butylamino-3-(o-furfuryloxyphenoxy)-2-propanol.
 10. A compound of claim 1 having the name 1-tert-butylamino-3-(o-tetrahydrofurfuryloxyphenoxy)-2-propanol. 